Comprehensive management of patients with superficial fungal infections: the role of sertaconazole nitrate.
The incidence of mycotic infections is on the rise in the United States. The failure of patients and clinicians to recognize a fungal infection early may lead to extensive, severe, and difficult-to-treat disease. Treatment decisions must include an awareness of the etiologic organism involved, the potential for long-term recurrence, symptoms such as inflammation and itching, and the importance of patient adherence to treatment. Sertaconazole nitrate, a broad-spectrum imidazole agent with antifungal, antibacterial, antiinflammatory, and antipruritic properties, is the topical antifungal agent most recently approved by the US Food and Drug Administration. A review of its mechanisms of action, pharmacokinetic profile, fungistatic and fungicidal activities, and clinical properties examines a substantial body of research findings that establish its efficacy, safety, and tolerability. Its use in the treatment of tinea pedis and other superficial mycotic infections is reviewed here.
Del Rosso
James Q
JQ
University of Nevada School of Medicine, Las Vegas, USA.
D000935:Antifungal Agents / Q000627:therapeutic use*; D003881:Dermatomycoses / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
D000935:Antifungal Agents; D007093:Imidazoles; D013876:Thiophenes; C061131:sertaconazole